Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

HIV-positive mothers with undetectable viral load can now safely breastfeed their infants, according to recently updated ...

The results indicate the potential of a yearly biomedical intervention for preventing HIV infection, the team stated. However, the small sample size of the study limits the broader generalization ...

North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...

I hope those living with HIV feel embraced and those who don’t can develop empathy and expand their understanding of what it means to live with the virus in this day and age.” “Oxygen Masks ...

Transposons, also known as jumping genes or mobile genetic elements as they can replicate and reinsert themselves in the genome, threaten the cell's genome integrity by triggering DNA rearrangements ...